Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response — AFR22

Myeloid Leukemia, Chronic Clinical Trial

Official title:
Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy

Status Terminated

Clinical Trial Summary

Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients. To increase molecular response ratio we decided to increase imatinib dose to limited resistance to this drug and to add zoledronate for it anti tumoral activity to increase anti leukemic effect. We plan to accrue 37 patients in 5 centers. We will analyse molecular expression of BCR-ABL transcript after 6 months of treatment, safety, duration of response, VEGF expression and LTgd production.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Myeloid Leukemia, Chronic

Clinical Trial Details

NCT number	NCT00210119
Study type	Interventional
Source	Institut Bergonié
Contact
Status	Terminated
Phase	Phase 2
Start date	July 12, 2006
Completion date	March 2009

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00114959` - Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)	Phase 2
Completed	`NCT00482703` - A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia	Phase 1/Phase 2
Terminated	`NCT02086487` - Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy	Phase 4
Recruiting	`NCT00445822` - Registration of Children With CML and Treatment With Imatinib	N/A
Completed	`NCT00478985` - Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia	N/A
Terminated	`NCT02543749` - DC Vaccination in CML	Phase 1/Phase 2
Completed	`NCT02222272` - Effect of 2nd Gen TKI in CML
Completed	`NCT01660607` - Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell	Phase 1/Phase 2
Completed	`NCT02890784` - Dasatinib Holiday for Improved Tolerability	Phase 3
Completed	`NCT00481247` - A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML	Phase 3